The PAMA Final Rule: What You Need to Know and Do NOW to Comply with the New Payment Rules and Protect Your Lab Revenue

Urgent New Lab Compliance Webinar

Purchase this URGENT G2 Intelligence Webinar for analysis on the Final Rule and what it means for laboratories in partnership with the American Clinical Laboratory Association.

Presenters: Peter M. Kazon
Senior Counsel, Alston & Bird
Legal Counsel, American Clinical Laboratory Association
Joyce Gresko
Senior Associate, Alston & Bird
Paul Sheives
Vice President, Reimbursement & Regulatory Policy
American Clinical Laboratory Association
Duration: 90 minutes
CEU Credits: 1.0
Price: $197.00

The highly anticipated PAMA Final Rule is just days away –
and your organization MUST be prepared

The new Protecting Access to Medicare Act of 2014 (PAMA) 216 regulations now nearing release – completely change the way Centers for Medicare and Medicaid Services determines payment amounts for laboratory services under the Clinical Laboratory Fee Schedule (CLFS).

Under the proposed new rules, labs that have the majority of their Medicare revenues paid under the CLFS or the Physician Fee Schedule (PFS) will be required to report private payor payment rates and corresponding test volumes.

And that’s just the tip of the iceberg. The new PAMA rules also confront affected labs with changes to HCPCS codes, payment rates, and ADLT pricing … along with tough new penalties for failure to comply … a new phase-in schedule … and much more!

Get the Help You Need to Comply with the New PAMA Rules

This special webinar will review and help you:

  • Understand the new PAMA 216 rules
  • Determine the implications of the first major reform of the Medicare laboratory test rate-setting system in three decades – and what it means for your organization
  • Define the process CMS will use going forward and establish prices for laboratory services furnished to Medicare beneficiaries
  • Get answers to the myriad of outstanding questions concerning how “applicable laboratories” will be required to report their private payor rates to CMS, including the data collection period
  • Gain insight into the host of coding reforms for clinical laboratory tests that are part of this historic overhaul of the fee schedule
  • What must now be reported to CMS
  • Penalties for non-compliance
  • And much more!

Make no mistake – with regulatory clearance imminent, you won’t want to miss this G2 Intelligence webinar in partnership with the American Clinical Laboratory Association to analyze the Final Rule and what it means for laboratories.

About Your Presenters

Peter M. Kazon
Senior Counsel, Alston & Bird and Legal Counsel, American Clinical Laboratory Association
Peter Kazon has more than 25 years of experience assisting companies and individuals in negotiating the complex legal and regulatory issues that healthcare providers routinely face. He counsels providers on matters involving Medicare coverage, reimbursement, billing, fraud and abuse, and Stark self-referral issues. His primary practice areas include advising clinical laboratories and diagnostic companies on regulatory and compliance matters and assisting companies with emerging medical technologies with coverage, coding and reimbursement issues. He assists companies on compliance with the Federal Food, Drug, and Cosmetic Act and its recent amendments, with particular attention to FDA actions affecting in vitro diagnostic products.

Kazon is a frequent speaker and writer on healthcare issues and sits on the editorial advisory board of Bloomberg BNA’s Medical Devices Law & Industry Report. He has been recognized as one of The Best Lawyers in America.


Joyce Gresko
Senior Associate, Alston & Bird
Joyce Gresko is an attorney in Alston & Bird’s Washington, D.C., office, where she is a member of the Healthcare and Legislative & Public Policy Groups. She focuses her practice on healthcare regulatory, legislative, and compliance matters. Her clients include clinical laboratories, durable medical equipment suppliers, hospitals, health care professional associations, and other healthcare entities. She assists clients on a daily basis to understand and resolve issues relating to Medicare and Medicaid payment and coding, federal and state fraud and abuse laws, effective compliance programs, and healthcare quality.

Gresko draws on her experience prior to becoming an attorney, which includes more than a decade as a public policy advocate and campaign professional and is currently a reading mentor through the Washington D.C. public school program Everybody Wins!


Paul Sheives
Vice President, Reimbursement & Regulatory Policy, American Clinical Laboratory Association
Paul Sheives is the Vice President, Reimbursement & Regulatory Policy at the American Clinical Laboratory Association, a Washington, D.C.-based association that represents the nation’s leading clinical laboratories on federal and state government policies impacting the industry. Its diverse membership consists of national, regional, esoteric, hospital, and nursing home laboratories that perform millions of tests each year to the benefit of patients. With a background in molecular biology, regulatory law, and reimbursement counseling, Sheives has represented companies throughout the spectrum of biotechnology.

Prior to ACLA, he was the Director of Diagnostics and Personalized Medicine Policy at the Biotechnology Industry Organization (BIO). Before BIO, he practiced in two large, international law firms as a legal associate in the areas of FDA and reimbursement law, and prior to that served as a regulatory science advisor. He holds a J.D. from the Georgetown University Law Center, a M.S. in molecular and cellular biology from the University of Texas Southwestern Medical Center at Dallas, and a B.S. in microbiology from the University of Texas at Arlington.